Cassava Sciences (SAVA) hogged the headlines last year both for good and bad reasons. The company’s Alzheimer’s disease (AD) candidate simufilam showed exceptional results in clinical trials – after 6 months, 9 months, and a 12-month analysis following treatment, patients’ cognitive behavior improved – impressing in what has always been a notoriously difficult to treat condition. But then the tables turned on the company, as accusations of data manipulation and unsound practices were made.
So, where is the company at right now? Given the company initiated two separate Phase 3 studies of simufilam (RETHINK-ALZ and REFOCUS-ALZ), H.C. Wainwright’s 5-star analyst Vernon Bernardino believes 2021 “ended strong.”
“With independent third-party confirmation by the prestigious journal, Neuroscience, that there was no evidence of data manipulation we believe the overhang that doggedly…
